[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

MP Advisors: Market Research Reports

MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.

MP Advisors unparalleled service includes:

  • Financial Analysis;
  • Competitive landscaping;
  • Macro Analysis;
  • Technology Transfer;
  • Mergers & Acquisitions;
  • Strategic planning;
  • Forecast.

Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.

More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.

Publications found: 456
Sort by:

ROCHE - Perjeta -First approved therapy in preoperative, early stage, HER2 positive breast cancer; Roche strengthening its breast cancer franchise

US$ 90.00

FDA granted accelerated approval to Roche’s Perjeta for the treatment of high risk, neoadjuvant breast cancer. This is the first drug to be approved for this indication and the approval was based on pathological ...

September 2013 2 pages

Basilea pharma - Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL!

US$ 140.00

Basilea pharma (BSLN) along with its partner, Astellas is co-developing antifungal Isavuconazole (PhIII) for invasive fungal infections. Isavuconazole demonstrated non-inferiority vs. voriconazole in its international PhIII, SECURE trial in pts ...

September 2013 5 pages

MITSUBISHI TANABE - Remicade Biosimilar in Japan: Rapid Movements in Competitive Landscape!

US$ 300.00

... than NK - Nichi-ikko (Aprogen/Sanofi-Table 3) is also preparing to launch biosimilar of Remicade by 2014/2015. As Nippon Kayaku...........Remicade in Japan is more used by............2014 NHI Price Revisions More Crucial than Remicade Biosimilar For Remicade! In the next NHI price revision due ...

September 2013 4 pages

CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately

US$ 140.00

... of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India ...

September 2013 2 pages

Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

US$ 2,500.00

... of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of ... care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity ...

September 2013 44 pages

MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth

US$ 140.00

Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature ... , please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.

September 2013 5 pages

Amgen (AMGN) - Onyx Acquisition + Maturing Pipeline + Biosimilar Opportunity = Better Poised Than Large Pharma!

US$ 140.00

Amgen (AMGN) announced the acquisition of Onyx pharma at $125/sh or $10.4b ($9.7b net of est. Onyx cash) in net cash, strengthening its Oncology/ Hematology drug portfolio ($7b in ...

September 2013 7 pages

Generic Advair - 3 years to go, but which generic companies are better poised?

US$ 140.00

... announced the draft guidance for the development of generic version of GSK’s Asthma / COPD drug – Advair (Fluticasone propionate + Salmeterol Xinafoate). The ... guidelines pave the way for generic companies to launch a substitutable and interchangeable version of Advair in the US market, which should ...

September 2013 3 pages

GSK - FDA Advisory committee positive on Anoro Ellipta - First once daily dual bronchodilator for US COPD patients

US$ 90.00

GSK and Theravance jointly announced that the FDA pulmonary allergy Drugs Advisory Committee recommended in favor of approval (11-2) for the once daily, lower dose ... getting impacted to that extent. The MAA (Europe) for Anoro has already been filed in Europe and expected to receive approval by the end ...

September 2013 2 pages

Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN

US$ 250.00

Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...

September 2013 7 pages

Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1,2, STELARA, GSK-1605786, Vercirnon, Traficet-EN

US$ 250.00

Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing ...

September 2013 7 pages

SymBio pharma - TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!

US$ 140.00

... gained Japan/Korea rights in 2011. Onconova Therapeutics (ONTX) debut in NASDAQ has been very encouraging and should percolate into SymBio especially ... ... For more detail please read our report on SymBio released on 3rd Sept. 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + ...

September 2013 3 pages

Edoxaban - HOTSUKAI VTE STUDY Results at ESC-13- Well differentiated and should carve its niche in VTE patients with PE/Renal impairment

US$ 90.00

... presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy ... Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with ...

September 2013 2 pages

Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain

US$ 140.00

... Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013 ... detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug ...

September 2013 6 pages

Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still!

US$ 200.00

Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: ... in pts with 2nd-line Higher Risk MDS vs. less than six months offered ... ). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON ... our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"

August 2013 11 pages

Ambit Biosciences (AMBI) - Early Approval of Quizartinib in RR-AML = A Risk Worth Taking

US$ 200.00

... kinase-3 inhibitor for acute myeloid leukemia, AML) from Astellas in 2013 armed AMBI to tap the unmet need in refractory/ relapsed AML (RR AML) and related hematological disorders ... read our report on Ambit released on 30th August 2013, titled, "Early Approval of Quizartinib in RR-AML = A Risk Worth Taking".

August 2013 10 pages

Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

US$ 2,500.00

... need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity ...

August 2013 37 pages

KYORIN, Flutiform Will Make its Japanese Debut Soon - A game changer for Kyorin!

US$ 200.00

... PAFSC committee recommendation, Flutiform (Fluticasone propionate + formoterol) fixed dose combination is likely to get Japanese approval in September. It will be the third ... MDI (Chart 1) and Symbicort Trubohaler. Key advantage with Flutiform is its faster onset of action which gives rapid relief from ...

August 2013 5 pages

INCYTE – JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!

US$ 140.00

... Survival analysis data from the PhII, RECAP trial of Ruxolitinib (L – JAKAFI for MF, oral JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis ... read our report released o 21st Aug., 2013 on INCY, titled “JAKAFI’s Label Expansion in Ref. Metastatic Pancreatic Cancer = Multi-Billion Potential!”

August 2013 3 pages

IPCA - We reiterate our market perform rating for IPCA and increase price target to Rs.740 by valuing the company at 18x of FY15 earnings. We expect revenue and earnings to grow by 16 -17% in next two

US$ 140.00

We reiterate our market perform rating for IPCA and increase price target to Rs.740 by valuing the company at 18x of ...

August 2013 5 pages

RANBAXY - Stretched Balance Sheet, a Weak Product Pipeline, and Uncertainty around Monetizing Exclusivities

US$ 140.00

Q2 CY-13 Result in Line: Sales grew by 8% QoQ primarily on account of higher Absorica (Isotretinoin) sales in US. US sales grew by 29% sequentially as company now has 14% share in Isotretinion (~$400m market). Excluding US, revenue across the geographies remained muted and grew by 1% sequentially and 2% yoy. ...

August 2013 6 pages

SHIONOGI - Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data from FLEMINGO Study and Approval of Trii FDC!

US$ 300.00

Tivicay (Dolutegravir) US Approval Comes with an Encouraging Broad Label. Focus Shifts on Data ... Study and Approval of Trii FDC! ViiVhealthcare today announced US approval of Tivicay (Dolutegravir) - it is approved both for treatment naïve and treatment experienced HIV patients ...

August 2013 3 pages

CADILA HEALTHCARE, We reiterate our outperform rating on Cadila; however, revise our price target down to Rs.950 (20x of FY15 earnings), owing to the delay in the approval of ANDA’s.

US$ 140.00

We reiterate our outperform rating on Cadila; however, revise our price target down to Rs.950 (20x of FY15 earnings), owing to the delay in the approval of ANDA’s. We lower our revenue ...

August 2013 10 pages

CIPLA , We reiterate our market perform rating on Cipla with a price target of Rs.415 (20x FY-15 earnings) as we expect

US$ 140.00

We reiterate our market perform rating on Cipla with a price target of Rs.415 (20x FY-15 earnings) as we expect 1) Sales growth to ...

August 2013 5 pages

NOVARTIS - String of Pearls- LDK378, Serelaxin followed by breakthrough designation for BYM338 (bimagrumab)

US$ 90.00

Novartis received break through designation from FDA for its third ...

August 2013 2 pages

TAEKDA, TAK-700 - Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo naïve pool and in earlier setting?

US$ 90.00

... interim analysis results from the ELM-PC 5 Phase 3 study of Orteronel (TAK-700) plus prednisone in chemo experienced prostate cancer patients. The interim ... were no major concerns. What to expect in Pre-chemo setting from TAK-700? Might demonstrate OS benefit compared to control arm but difficult to beat ...

August 2013 5 pages

Novartis, 2013 Outlook revised but below expectations

US$ 90.00

Novartis reported strong 2Q-2013 financial results due to the absence of Diovan generics in the US. For the same reason, Novartis has revised ... its earning guidance for the full year 2013. It ... low-single digit rate. We see the revision in guidance as inadequate and not reflective of ...

August 2013 3 pages

Sanofi Q2-2013 Earnings – 2013 EPS Outlook trimmed

US$ 90.00

Sanofi reported lower than expected 2Q-2013 financial results due to greater than anticipated impact of genericization, foreign ...

August 2013 3 pages

TAKEDA, Vortioxetine (Brintellix) – US Approval for MDD Likely in October – Competitive Enough Against Genericized MDD Market, Yet Maturing Late Stage Pipeline Candidates Warrant A Close Watch!

US$ 140.00

Takeda’s late stage pipeline candidate – Vortioxetine (Filed, Partnered with Lundbeck, US PDUFA on October 2nd) is expected to get ... present an attractive market for new entrants. Reported PhIII data of Vortioxetine look. However, other pipeline candidates are chasing ...

August 2013 4 pages

Merck – One timers and Forex weigh on Merck’s guidance

US$ 90.00

MRK reported its 2Q 2013 results: the net sales decline by 11% ($11.0b) including negative foreign exchange impact by 3% compared to last year. Company reiterated its 2013 non-GAAP EPS guidance ($3.45 and $3.55) while revised its GAAP EPS to be between $1.84 and $2.05 (previous $1.92-2.16). MRK expects its ...

August 2013 1 pages

NATCO, Dismissal of Litigation over “Gad Patents” is Positive, Potential Launch Timing Still Contingent on Federal Circuit Outcome

US$ 90.00

US district court (NY Southern) granted a motion by Mylan and Sandoz to dismiss the litigation over 4 non OB patents (‘938, ‘802, ‘359 – expiring in Sept, 2019 and ... the molecular weight of a sample of Glatiramer Acetate. The litigation has been dismissed as Mylan and Sandoz agreed not to use certain polypeptide ...

July 2013 1 pages

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed

US$ 800.00

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm ... Cancer Table 3: Upcoming Milestones- TAK-700 Table 4: Reported Clinical Data of TAK-700 Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001 Table ...

July 2013 14 pages

Merck -Suvorexant delayed but no additional studies required is a sigh of relief

US$ 90.00

FDA recently issued a complete response letter to MRK’s Suvorexant. As per the complete response letter, the USFDA will need ... not be approved. We see the launch timelines delayed by atleast 12 to 18 months. In case of the 10mg dose Merck would have to conduct an additional stability study ...

July 2013 1 pages

Biogen Idec – Poised to Grow Beyond MS

US$ 140.00

... detail, please read our report released on July 8, 2013, titled, “Poised to Grow Beyond MS”.

July 2013 7 pages

Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!

US$ 140.00

... inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) and Incyte’s (INCY) maturing pipeline. PhII data of oral RA drug Barcitinib ( ... please read our report released on June 18, 2013, titled, “Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!”

June 2013 9 pages

Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies

US$ 2,500.00

... of oral drugs and oral formulations of injectable only drugs. Global injectable drug delivery market is expected to be worth $29b by 2015. Novel drug delivery systems (NDDS) ... drug technologies in a manner that improves the benefits to the patients. The generic market with reference to innovative molecule ...

June 2013 123 pages

Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth

US$ 140.00

Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors ... detail, please read our report released on June 06, 2013, titled, “Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth”.

June 2013 3 pages

MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth

US$ 140.00

Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling ... detail, please read our report released on June 05, 2013, titled, “MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth”.

June 2013 5 pages

ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013

US$ 140.00

... / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead ... detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold ...

May 2013 12 pages

ASTRAZENECA: AZN: Omthera Acquisition – Valuations defensive, leaves room for upside

US$ 90.00

AstraZeneca today announced acquisition of Omthera Pharma for $260m in cash and $120m in form of contingent value rights. The acquisition gives AstraZeneca access to fish oil product Epanova ...

May 2013 3 pages

Infinity Pharma – ASCO ‘13 to Reinstate Faith in IPI-145!

US$ 140.00

Infinity (INFI) shares down on concerns that IPI-145 (PI3K-delta, ... detail, please read our report released on May 28, 2013, titled, “ASCO ‘13 to Reinstate Faith in IPI-145!”

May 2013 4 pages

Halozyme – HyQvia Approval in EU and Upcoming milestones = Upside

US$ 140.00

... drugs) has gained 50% of market share in 16 months of launch showing acceptability of Halozyme’s (HALO) ENHANZE platform (recombinant human hyaluronidase, rHuPH20 use in the ... detail, please read our report released on May 24, 2013, titled, “HyQvia Approval in EU and Upcoming milestones = Upside”.

May 2013 4 pages

Pharmacyclics – Ibrutinib: A Game Changer – 3 Breakthrough Therapy Designations + More Data ASCO/EHA ‘13

US$ 140.00

... FL) leads in the new treatment options in development for hematological malignancies. Ibrutinib, a small molecule is being studied as a monotherapy and has shown ... please read our report released on May 24, 2013, titled, “Ibrutinib: A Game Changer – 3 Breakthrough Therapy Designations + More Data @ ASCO/EHA ...

May 2013 10 pages

Para IV Plus Database

US$ 8,000.00

... undisclosed settlement dates, based on available facts. In other words, Para IV Plus is not merely a database but is a tool with in-depth insights for every ... gives list of potential API buyers To a pharma company desirous of banking on the Para IV litigations, this tool will help them strategize their entry ...

April 2013

Japan Pharma Database

US$ 15,000.00

Pricing: Japan Database: $15,000/- subscription p/a Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets ... reliable Source in public domain 5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas ...

April 2013

ASTELLAS, ZERIA - Acofide: Superior Enough To Create a Niche and Stand Differentiated Amongst the Generic Functional Dyspepsia Market

US$ 90.00

Astellas/Zeria in March received approval of Acofide (Acotiamide, Acetylcholine esterase inhibitor, PhIII EU/PhII US) for treatment of Functional dyspepsia (FD) diagnosed by ROME III criteria in Japan ... creates a market for Acofide. Acofide’s differentiated mechanism of action, superior efficacy and clean safety ...

April 2013 4 pages

PFIZER – MERCK alliance for Ertugliflozin – Not a better partner than Merck

US$ 90.00

Merck-Pfizer deal for SGLT2 inhibitor - Ertugliflozin is positive and we see Merck as an ideal partner. The fixed dose combination of Ertugliflozin and Januvia ...

April 2013 2 pages

ENDOCYTE - Small and Powerful Targeted Therapy!

US$ 140.00

Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s ... our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!

April 2013 11 pages

Xtandi- The Real Potential and the Astellas Part!

US$ 500.00

Xtandi- The Real Potential and the Astellas Part! Expectations that Xtandi (Enzalutamide, Approved, Prostate Cancer) is going to bring a paradigm shift to ... Although, the clinical profile of Xtandi (steroid free regimen, better safety and efficacy than Zytiga) carries potential to compete with Casodex/Zytiga ...

April 2013 12 pages

ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!

US$ 140.00

... acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead’s Sofosbuvir (PhIII, PMI) in combination with RBV ... our initiation report released on 17th April, 2013 on ENTA titled “Debut of a Star- 2nd in the Oral IFN free HCV Drug Race ...

April 2013 8 pages

Filters

Search

Categories

1
1
2
1
7
7
10
1
19
4
10
25
4
208
2
2
5
125
1
21

Publishers

456

Regions

1
1
6
52
64
22
4
4
10
1
1
28
4
160
6
91
1

Price

Date

Pages

Offers

7
5